$100 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much Today
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 27.31% on an annualized basis…
SAVA, LLY, IBB: Why These Alzheimer’s Related Stocks Are Volatile On Friday
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to
FDA Grants Accelerated Approval For Alzheimer’s Disease Treatment
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors’ Attention Today
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds.
Cassava Sciences Announces Completion of Dosing In Open-Label Study Of Simufilam For Alzheimer’s Disease
Outside Biostatisticians with Specific Expertise in Alzheimer's Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset.
Clinical Dataset May Be Announced Approximately Year-End 2022,
Cassava Sciences Announces Closing Of $50M Registered Direct Offering; Shares Move Higher
Cassava Sciences, Inc. (NASDAQ:SAVA) (the "Company" or "Cassava Sciences"), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the closing of its previously
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Cassava Sciences Has Initiated And Started Enrollment For A New Open Label Extension To Their Phase 3 Trial Of Simufilam For The Treatment Of Alzheimer’s Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam - Full Text View - ClinicalTrials.gov
Brief Summary:
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam
EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.